Warm Greetings on yet another edition of The Prescription!
Reporting the side effects of a drug could help determine if the medicine should stay or be pulled off shelves. A medicine labelled safe for clinical use after trials could still be found to be dangerous. This data is important for a drug to be termed safe for consumption. Unfortunately, India has been poorly reporting adverse drug reactions in the last few years as Pharmacovigilance existed only on paper back then. Things seem to be improving but there’s still lots to achieve. Read our PSM India Capsules to know the reasons behind India’s poor track record in reporting ADRs.
While the Union government has approved the roll-out of the WHO-recommended new triple-drug therapy (TDT) in four select districts, including one in Maharashtra, to eliminate lymphatic filariasis (LF) from the country, the Commerce Ministry exempts pharma companies from barcoding for exports for six months; read this and more about red band warnings to be appearing on all listed drugs from now on under Drug Laws and Policy Injections.
Do not hesitate to mail your comments on this edition to help us further improve. We appreciate your support and trust in us and are happy to have you as our loyal reader.
Feedback is what keeps us going. Should you have any query or question, please feel free to get in touch with us. Write to me on firstname.lastname@example.org
Stay Healthy. Stay Protected.